Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8654788 | 0.88 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL8388744 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL8386008 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL8652481 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8384174 | 0.80 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL3246481 | 0.76 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL8974275 | 0.75 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL8653268 | 0.75 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL8652490 | 0.74 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL8652923 | 0.74 | PTGS2 (0.60) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479385-B1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | SEARLE LLC (US) | 2008-07-02 | — | — | EP | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-1479385-A1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. Searle LLC (US) | 2004-11-24 | — | — | EP | claimed |
| EP-1463500-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-06 | — | — | EP | claimed |
| US-20040186154-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | SEIBERT KAREN (US) | 2004-09-23 | — | — | US | claimed |
| US-20030211163-A1 | Combination antiviral therapy | PHARMACIA & UPJOHN COMPANY | 2003-11-13 | — | — | US | claimed |
| US-20030199482-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | PHARMACIA CORPORATION | 2003-10-23 | — | — | US | claimed |
| US-20030153801-A1 | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease | PHARMACIA CORPORATION | 2003-08-14 | — | — | US | claimed |
| WO-2003059347-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20020035156-A1 | Combination therapy in the prevention of cardiovascular disorders | RONIKER BARBARA (US) | 2002-03-21 | — | — | US | claimed |
| US-20010047024-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. SEARLE & CO. | 2001-11-29 | — | — | US | claimed |
| EP-0724566-B1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1998-10-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211163-A1 | Combination antiviral therapy | EIF2AK2, ZC3HAV1, VHL | PTGS2 1846/4885PTGS1 1821/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | CSGALNACT1, PTGS2, PTGS1 | PTGS2 2/4885PTGS1 3/4885 |
| US-20010047024-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20020035156-A1 | Combination therapy in the prevention of cardiovascular disorders | FABP3, TNNT2, TNNI3 | PTGS2 6/4885PTGS1 20/4885 |
| US-20030199482-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | HMGCR, HMGB2, HMGB3 | PTGS2 7/4885PTGS1 18/4885 |
| US-20040186154-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | HMGCR, HMGB2, HMGB3 | PTGS2 7/4885PTGS1 18/4885 |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PTGS2, PTGS1, UGGT1 | PTGS2 1/4885PTGS1 2/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.